Get the Stockscreener App
1.63
0.61%
-0.01
Windtree Therapeutics Inc Stock (WINT) Latest News
Windtree Therapeutics Announces Reverse Stock Split to Maintain Nasdaq Compliance - MSN
Windtree Therapeutics Regains Nasdaq Compliance - MSN
Windtree reports positive Phase 2b study on heart failure therapy - MSN
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics - Marketscreener.com
Massive 60% Cost Cut: How PHEXXI's New Deal Transforms Global Contraceptive Access - StockTitan
US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert - Benzinga
Windtree Therapeutics IncOn March 20, Entered License And Supply Agreement With Evofem BiosciencesSEC Filing - Marketscreener.com
Windtree Therapeutics regains compliance with Nasdaq listing rules - TipRanks
Windtree Therapeutics Regains Compliance With Nasdaq Listing Rules For Continued Listing - Nasdaq
Windtree Therapeutics Regains Nasdaq Compliance Over Minimum Share Price Rule - Marketscreener.com
Windtree Therapeutics regains Nasdaq compliance - Investing.com India
Evofem Reports Fourth Consecutive Year of Net Sales Growth - Quantisnow
Evofem Reports Fourth Consecutive Year of Net Sales Growth -March 24, 2025 at 08:31 am EDT - Marketscreener.com
Evofem Posts Record 4th Year Growth: Revenue Up 6% as Operating Costs Plunge 27% - StockTitan
Windtree Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Nasdaq
Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules - The Manila Times
Windtree Therapeutics Dodges Delisting: How The Biotech Company Saved Its Nasdaq Status - StockTitan
Why AZEK Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Biotech Stocks To Consider – March 20th - Defense World
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Windtree Therapeutics and Evofem Announce Agreement to Lower Manufacturing Costs for PHEXXI® - MSN
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Windtree shares rise as it announces agreement to become sourcing partner for Evofem - MSN
Crude Oil Gains Over 1%; US Weekly Jobless Claims Increase - Benzinga
Windtree Therapeutics (WINT) Climb Amid New Licensing Deal - Stocks Telegraph
Another Day, Another Biotech Ripping Before The Bell - The Globe and Mail
Dow Gains Over 100 Points; Accenture Shares Plunge After Q2 Results - Benzinga India
What's Going On With Windtree Therapeutics Shares Thursday? - Benzinga
Windtree to become sourcing partner for Evofem Biosciences - TipRanks
Windtree Signs Deal to Become Sourcing Partner for Evofem's Contraceptive Vaginal Gel; Shares Rise - Marketscreener.com
Windtree partners with Evofem for contraceptive gel supply - Investing.com
Windtree's Game-Changing Deal: Manufacturing Rights to $19M FDA-Approved Contraceptive - StockTitan
Critical Comparison: AIM ImmunoTech (NYSE:AIM) & Windtree Therapeutics (NASDAQ:WINT) - Defense World
Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Expands By 44.9% - Defense World
Reviewing Atyr PHARMA (NASDAQ:ATYR) & Windtree Therapeutics (NASDAQ:WINT) - Defense World
FY2024 Earnings Forecast for WINT Issued By Zacks Small Cap - Defense World
Windtree Therapeutics Secures Patent for Istaroxime IV Formulation in Acute Heart Failure - MSN
Windtree (WINT) Sees Pre-Market Surge Following Key Patent Milestone - Stocks Telegraph
SponsoredImpartialComprehensive - Research Tree
Windtree Therapeutics (WINT) Shares Are Volatile: What's Going On? - Benzinga
WINT: Advancing Lead Asset; Leveraging Strategic M&A to Potentially Shorten Timeline to Revenue Generation – Initiating Coverage - Yahoo Finance
WINTWindtree Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Windtree Announces Istaroxime Notice of Allowance from the U.S. Patent and Trademark Office for Acute Heart Failure - Yahoo Finance
Windtree Therapeutics Files Patent Application in India for Istaroxime, Advancing Arrhythmia Treatment - MSN
Discovery Laboratories Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015 - Marketscreener.com
Comparing Senti Biosciences (NASDAQ:SNTI) and Windtree Therapeutics (NASDAQ:WINT) - Defense World
Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Large Drop in Short Interest - Defense World
Windtree Files Istaroxime Cardiogenic Shock and Prevention of Arrythmias Patent for India - The Manila Times
Windtree's Cardiac Drug Patent Filing Targets India's Massive MarketPhase 3 Trials on Horizon - StockTitan
Inhibikase Therapeutics (NYSE:IKT) vs. Windtree Therapeutics (NASDAQ:WINT) Critical Survey - Defense World
WINT stock touches 52-week low at $0.1 amid steep annual decline - Investing.com
Windtree Therapeutics, Inc. Announces Reverse Stock Split - GlobeNewswire
Windtree Therapeutics approves 1-for-50 reverse stock split - MSN
Windtree Therapeutics Approves 1-for-50 Reverse Stock Split; Shares Fall Pre-Bell -February 18, 2025 at 09:35 am EST - Marketscreener.com
Windtree Therapeutics Announces Reverse Stock Split Approval - TipRanks
0.08%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):